Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medpace Holdings has the GF Score of 95, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Medpace Holdings
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Medpace Holdings (FRA:01P) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Medpace Holdings GF Score Related Terms
FRA:01P vs ICLR, RVTY, CRL: GF Score Comparison
For the Diagnostics & Research subindustry, Medpace Holdings's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medpace Holdings GF Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Medpace Holdings's GF Score distribution charts can be found below:
* The bar in red indicates where Medpace Holdings's GF Score falls into.
Medpace Holdings (FRA:01P) has a GF Score of 95 as of Jul. 25, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Medpace Holdings and its competitors. This is near median its historical median of 88.00. Over the past decade, Medpace Holdings' GF Score has ranged from 18.00 to 99.00.
Is Medpace Holdings' GF Score too high?
Medpace Holdings' current GF Score of 95 is near median its 10-year median of 88.00. Over the past 10 years, this metric has ranged from a low of 18.00 to a high of 99.00. Overall, Medpace Holdings has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medpace Holdings' GF Score compare to ICLR and RVTY?
Medpace Holdings' GF Score of 95 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Medpace Holdings' own GF Score has ranged from 18.00 to 99.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Diagnostics & Research company?
A good GF Score depends on the Medical Diagnostics & Research industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Medpace Holdings and its competitors. Medpace Holdings's current GF Score is 95, which is near median its own 10-year median of 88.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medpace Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medpace Holdings (FRA:01P) is currently considered Modestly Overvalued. The stock's GF Value™ is €463.14, compared to a current price of €530.40 — trading 14.5% above its estimated fair value. The current GF Score is 95, which is near median its 10-year median of 88.00. Medpace Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Medpace Holdings (FRA:01P), the current GF Score is 95 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medpace Holdings (FRA:01P) Overvalued in 2026?
Based on GuruFocus' analysis, Medpace Holdings stock appears to be overvalued.
The current stock price of €530.40 is trading 14.5% above its estimated GF Value™ of €463.14.
GuruFocus considers Medpace Holdings to be Modestly Overvalued.
Key valuation signals for FRA:01P:
GF Score: 95 (near median its 10-year median of 88.00)
GF Value™: €463.14 vs. price of €530.40 (14.5% above fair value)
No single metric tells the full story. See the FRA:01P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.
95GF Score
Get the complete analysis for FRA:01P
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:01P has been successfully added to your 
